Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)2022-07-072022-07-072022-02-09O'Bryant, S. E., Zhang, F., Petersen, M., Hall, J., Johnson, L. A., Yaffe, K., Braskie, M., Rissman, R. A., Vig, R., Toga, A. W., & HABLE Study Team (2022). Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. Alzheimer's & dementia (Amsterdam, Netherlands), 14(1), e12267. https://doi.org/10.1002/dad2.122672352-8729https://hdl.handle.net/20.500.12503/31538Introduction: We sought to examine a magnetic resonance imaging (MRI)-based marker of neurodegeneration from the AT(N) (amyloid/tau/neurodegeneration) framework among a multi-ethnic, community-dwelling cohort. Methods: Community-dwelling Mexican Americans and non-Hispanic White adults and elders were recruited. All participants underwent comprehensive assessments including an interview, functional exam, clinical labs, informant interview, neuropsychological testing and 3T MRI of the brain. A neurodegeneration MRI meta-region of interest (ROI) biomarker for the AT(N) framework was calculated. Results: Data were examined from n = 1305 participants. Mexican Americans experienced N at significantly younger ages. The N biomarker was significantly associated with cognitive outcomes. N was significantly impacted by cardiovascular factors (e.g., total cholesterol, low-density lipoprotein) among non-Hispanic Whites whereas diabetes (glucose, HbA1c, duration of diabetes) and sociocultural (household income, acculturation) factors were strongly associated with N among Mexican Americans. Discussion: The prevalence, progression, timing, and sequence of the AT(N) biomarkers must be examined across diverse populations.http://creativecommons.org/licenses/by-nc-nd/4.0/Alzheimer's diseaseHispanicdiversitymild cognitive impairmentneurodegenerationAlzheimer DiseaseCognitive DysfunctionMexican AmericansAmyloidBiomarkersArticleCopyright © 2021 The Authors.141